secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001600620-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q4 2024 net income $1.4M on 33% revenue growth, LUPKYNIS sales up 36% YoY
--------------------------------------------------------------------------------

- Q4 total revenue $59.9M (+33% YoY); net product sales $57.6M (+36%); license revenue $2.3M (-18%).
- Q4 net income $1.4M vs $(26.9)M loss; full year net income $5.8M vs $(78.0)M loss.
- Cash flow from operations Q4 $30.1M (+110% YoY); full year $44.4M vs $(33.5)M.
- 2025 guidance: total revenue $250-260M, net product sales $240-250M; AUR200 Phase 1 data expected Q2 2025.
- Cash $358.5M at Dec 31, 2024; repurchased 6.1M shares for $41M in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/0001600620-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/auph-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001600620-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer